A Glass Act - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Glass Act
Duke University researchers have found a possible alternative to lyophilization.


Pharmaceutical Technology
Volume 34, Issue 7, pp. 14


Erik Greb
Most biopharmaceutical companies lyophilize products to dehydrate them and extend their shelf lives. But manufacturers may one day have a new technique that achieves the same goals more quickly.

David Needham, Duke University engineer and chemist, recently developed a process that dries proteins by turning them into glassy microbeads. The transformation occured when Needham's team used a micropipette to release droplets of water-dissolved protein into decanol, an organic solvent.

When water was restored to glassified test proteins, the proteins retained all or most of their original activity. The water that remained in the microbeads was not enough to allow bacteria or fungi to grow. These results suggest that glassification could be a good way to preserve biopharmaceuticals.

The microbeads are not as viscous as lyophilized proteins, so they are unlikely to clog syringes, according to Needham's research. Also, like multiparticulates, the glassified proteins potentially could be covered with polymers for delayed release.

The glassification process takes minutes, while lyophilization sometimes takes days. The new process is cheaper than lyophilization, too, because it requires no specialized equipment.

If Needham's technique can work well in an industrial setting, it could save biopharmaceutical manufacturers money without harming proteins or posing risks to patients. Lyophilization is not the best process for every protein, but, thanks to Needham's team, the industry could soon have another trick up its sleeve.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here